Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “HER2-positive Carcinoma of Breast”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Testing effectiveness (Phase 2)Active Not RecruitingNCT03368729
What this trial is testing

Niraparib in Combination With Trastuzumab in Metastatic HER2+ Breast Cancer

Who this might be right for
Metastatic Breast CancerHER2 Positive Breast Carcinoma
University of Alabama at Birmingham 46
Not applicableStudy completedNCT06655545
What this trial is testing

18F-fluoroestradiol (18F-FES) PET/CT Guided First-line Treatment for HR+/HER2- Metastatic Breast Cancer Patients

Who this might be right for
Breast Cancer
Fudan University 473
Not applicableStudy completedNCT04276272
What this trial is testing

D4 Choline Breast PET/CT

Who this might be right for
HER2-negative Breast CancerER Positive Breast CancerMetastatic Breast Cancer
Imperial College London 6
Not applicableUnknownNCT03655353
What this trial is testing

68Ga-ABY-025 PET for Non-invasive Quantification of HER2-expression in Advanced Breast Cancer

Who this might be right for
HER2-positive Breast Cancer
Henrik Lindman 160
Testing effectiveness (Phase 2)Ended earlyNCT03499353
What this trial is testing

Talazoparib For Neoadjuvant Treatment Of Germline BRCA1/2 Mutation Patients With Early Human Epidermal Growth Factor Receptor 2 Negative Breast Cancer

Who this might be right for
Early Breast Cancer
Pfizer 61
Not applicableUnknownNCT05169853
What this trial is testing

Programmed Death-Ligand1 Expression in Her-2 Positive and Triple Negative Breast Cancer

Who this might be right for
Triple Negative Breast CancerHER2-positive Breast Cancer
Ain Shams University 80
Testing effectiveness (Phase 2)Study completedNCT03395899
What this trial is testing

Pre-operative Immunotherapy Combination Strategies in Breast Cancer

Who this might be right for
Breast CancerEstrogen Receptor-positive Breast Cancer
Queen Mary University of London 71
Large-scale testing (Phase 3)Looking for participantsNCT05232916
What this trial is testing

Phase 3 Study to Evaluate the Efficacy and Safety of HER2/Neu Peptide GLSI-100 (GP2 + GM-CSF) in HER2/Neu Positive Subjects

Who this might be right for
Breast Cancer
Greenwich LifeSciences, Inc. 2,250
Not applicableLooking for participantsNCT06035016
What this trial is testing

Pyrotinib Plus Capecitabine for Adjuvant Treatment of HER2 Positive Early-stage Breast Cancer

Who this might be right for
HER2-positive Breast CancerEarly-stage Breast Cancer
Peking Union Medical College Hospital 300
Large-scale testing (Phase 3)Active Not RecruitingNCT06747338
What this trial is testing

A Phase III Study of KN026 in Combination With HB1801 ± Carboplatin as Neoadjuvant Treatment for Early or Locally Advanced HER2-Positive Breast Cancer

Who this might be right for
Early or Locally Advanced HER2-positive Breast Cancer
Shanghai JMT-Bio Inc. 520
Testing effectiveness (Phase 2)WithdrawnNCT04273555
What this trial is testing

Monitoring Early Response to Targeted Therapy in Stage IV HER2+ Breast Cancer Patients With Advanced PET/MR Imaging

Who this might be right for
HER2-positive Breast Cancer
University of Alabama at Birmingham
Testing effectiveness (Phase 2)Study completedNCT04072952
What this trial is testing

A Phase 1/2 Trial of ARV-471 Alone and in Combination With Palbociclib (IBRANCE®) in Patients With ER+/HER2- Locally Advanced or Metastatic Breast Cancer

Who this might be right for
Breast Cancer
Arvinas Estrogen Receptor, Inc. 217
Testing effectiveness (Phase 2)Study completedNCT00885755
What this trial is testing

Herceptin (Trastuzumab)and Biomarkers in Patients With HER2-Positive Metastatic Breast Cancer

Who this might be right for
Breast Cancer
Hoffmann-La Roche 33
Large-scale testing (Phase 3)Looking for participantsNCT07762885
What this trial is testing

Omission of Adjuvant Radiotherapy in Low- and Intermediate-Risk Ductal Carcinoma In Situ After Breast-Conserving Surgery

Who this might be right for
Ductal Carcinoma In Situ, DCIS
Fudan University 636
Testing effectiveness (Phase 2)Active Not RecruitingNCT03304080
What this trial is testing

Anastrozole, Palbociclib, Trastuzumab and Pertuzumab in HR-positive, HER2-positive Metastatic Breast

Who this might be right for
Breast NeoplasmsBreast Diseases
Icahn School of Medicine at Mount Sinai 44
Early research (Phase 1)Active Not RecruitingNCT04704661
What this trial is testing

Testing the Combination of Two Anti-cancer Drugs, DS-8201a and AZD6738, for The Treatment of Advanced Solid Tumors Expressing the HER2 Protein or Gene, The DASH Trial

Who this might be right for
Advanced Breast CarcinomaAdvanced Colon CarcinomaAdvanced Colorectal Carcinoma+37 more
National Cancer Institute (NCI) 51
Not applicableUnknownNCT02627703
What this trial is testing

(Oncotype DX®) in Estrogen Receptor Positive (ER+) HER-2 Negative (HER 2-) 1-3 Node Positive (pN1) Breast Cancer

Who this might be right for
Breast Cancer
British Columbia Cancer Agency 80
Not applicableStudy completedNCT01564368
What this trial is testing

DWI in Assessing Treatment Response in Patients With Breast Cancer Receiving Neoadjuvant Chemotherapy

Who this might be right for
Breast Cancer
American College of Radiology Imaging Network 406
Not applicableStudy completedNCT02286362
What this trial is testing

An Observational Study of the Safety of Herceptin Given Subcutaneously in Patients With Early HER2-positive Breast Cancer

Who this might be right for
Breast Cancer
Hoffmann-La Roche 510
Testing effectiveness (Phase 2)Study completedNCT04296162
What this trial is testing

Oral Vinorelbine or Capecitabine Combined With Trastuzumab as Adjuvant Treatment for Patients With Lymph Node Negative, HER-2 Positive and Small Tumor Size Breast Cancer (ORCHID)

Who this might be right for
Breast Cancer
Fudan University 182
Next Page